203 related articles for article (PubMed ID: 27529763)
1. Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers.
Duan K; Mete O
Cancer Cytopathol; 2016 Dec; 124(12):871-884. PubMed ID: 27529763
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
Yang Z; Klimstra DS; Hruban RH; Tang LH
Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
[TBL] [Abstract][Full Text] [Related]
3. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts.
Kim JY; Hong SM
Arch Pathol Lab Med; 2016 May; 140(5):437-48. PubMed ID: 27128301
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine tumor biomarkers: From monoanalytes to transcripts and algorithms.
Modlin IM; Bodei L; Kidd M
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):59-77. PubMed ID: 26971844
[TBL] [Abstract][Full Text] [Related]
5. Novel Finding of Paired Box 5 (PAX5) Cytoplasmic Staining in Well-differentiated Rectal Neuroendocrine Tumors (Carcinoids) and Its Diagnostic and Potentially Prognostic Utility.
Fu Z; Zuo C; Sheehan CE; Patil DT; Lin J; Yang Z; Lee H
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):454-460. PubMed ID: 29561272
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.
Uccella S; La Rosa S; Volante M; Papotti M
Endocr Pathol; 2018 Jun; 29(2):150-168. PubMed ID: 29520563
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors.
Galván JA; Astudillo A; Vallina A; Fonseca PJ; Gómez-Izquierdo L; García-Carbonero R; González MV
Am J Clin Pathol; 2013 Jul; 140(1):61-72. PubMed ID: 23765535
[TBL] [Abstract][Full Text] [Related]
8. Pathological diagnosis and tumor markers.
Milione M; Seregni E
Tumori; 2010; 96(5):810-6. PubMed ID: 21302637
[TBL] [Abstract][Full Text] [Related]
9. An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.
Bellizzi AM
Adv Anat Pathol; 2020 May; 27(3):114-163. PubMed ID: 32205473
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
11. Co-expression of TTF-1 and neuroendocrine markers in the human fetal lung and pulmonary neuroendocrine tumors.
Miskovic J; Brekalo Z; Vukojevic K; Miskovic HR; Kraljevic D; Todorovic J; Soljic V
Acta Histochem; 2015; 117(4-5):451-9. PubMed ID: 25722034
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine Differentiation in Thymic Carcinomas: A Diagnostic Pitfall: An Immunohistochemical Analysis of 27 Cases.
Weissferdt A; Moran CA
Am J Clin Pathol; 2016 Mar; 145(3):393-400. PubMed ID: 27124922
[TBL] [Abstract][Full Text] [Related]
13. Gastric neuroendocrine neoplasms and related precursor lesions.
La Rosa S; Vanoli A
J Clin Pathol; 2014 Nov; 67(11):938-48. PubMed ID: 25053544
[TBL] [Abstract][Full Text] [Related]
14. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.
Klimstra DS; Modlin IR; Adsay NV; Chetty R; Deshpande V; Gönen M; Jensen RT; Kidd M; Kulke MH; Lloyd RV; Moran C; Moss SF; Oberg K; O'Toole D; Rindi G; Robert ME; Suster S; Tang LH; Tzen CY; Washington MK; Wiedenmann B; Yao J
Am J Surg Pathol; 2010 Mar; 34(3):300-13. PubMed ID: 20118772
[TBL] [Abstract][Full Text] [Related]
15. [Changes in the concept of neuroendocrine tumor].
Sasano H
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1602-5. PubMed ID: 19838016
[TBL] [Abstract][Full Text] [Related]
16. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
[TBL] [Abstract][Full Text] [Related]
17. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
Lindholm DP; Oberg K
Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and diagnostic value of epithelial to mesenchymal transition markers in pulmonary neuroendocrine tumors.
Galván JA; Astudillo A; Vallina A; Crespo G; Folgueras MV; González MV
BMC Cancer; 2014 Nov; 14():855. PubMed ID: 25413006
[TBL] [Abstract][Full Text] [Related]
20. Expression of Sex Determining Region Y-Box 2 and Pancreatic and Duodenal Homeobox 1 in Pancreatic Neuroendocrine Tumors.
Akiyama T; Shida T; Yoshitomi H; Takano S; Kagawa S; Shimizu H; Ohtsuka M; Kato A; Furukawa K; Miyazaki M
Pancreas; 2016 Apr; 45(4):522-7. PubMed ID: 26491904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
